Modified PAR receptors, their preparation and their uses for selecting compounds which modulate PAR activity
AssigneePfizer Inc.
InventorsClaire Berthelier, Claire Bigogne, Stephane Milano, Emmanuel Normant
Life of this patent
Estimating the term…
Loading patent…
AssigneePfizer Inc.
InventorsClaire Berthelier, Claire Bigogne, Stephane Milano, Emmanuel Normant
Estimating the term…
The invention describes novel PAR polypeptides and uses thereof. It relates in particular to PAR polypeptides lacking their functional endogenous activating peptide and capable of interacting constitutively with a ligand for a wild-type PAR. The invention also lies in methods of screening for active compounds, using modified PAR polypeptides, and also in the therapeutic use of identified compounds, in particular for the treatment of inflammation, of allergies, of diseases affecting the CNS, of neurodegeneration, or of psychiatric or cardiovascular diseases, and also in methods and compositions which can be used for this purpose. Other subjects of the invention include nucleic acids encoding a modified PAR, vectors and recombinant host cells and transgenic animals containing them, and also their uses in the context of a therapeutic, diagnostic or screening approach, for example.
A modified PAR polypeptide, said modified polypeptide having an endogenous activating peptide made non functional and said modified PAR polypeptide being capable of interacting with an exogenous ligand for a wild-type PAR receptor, wherein said exogenous ligand has an ED50 for said modified PAR polypeptide significantly higher than its ED50 for a wild type PAR receptor.
A method of screening for, selecting or identifying a PAR activity modulator compound, said method comprising the steps of:
Dependencies are inferred from the claim text.